Overdose of Boots IBS Relief in details
In cases where Duspatalin was taken in overdose, symptoms were either absent or mild and usually rapidly reversible.
Symptoms: Theoretically, central nervous system excitability may occur in cases of overdose. In cases where Boots IBS Relief was taken in overdose, symptoms were either absent or mild and usually rapidly reversible. Observed symptoms of overdose were of neurological and cardiovascular nature.
Treatment: No specific antidote is known and symptomatic treatment is recommended. Gastric lavage should only be considered in case of multiple intoxication within about 1 hr. Absorption reducing measures are not necessary.
Boots IBS Relief warnings
Boots IBS Relief has proved to be well- tolerated in therapeutic doses.
Though experiments in rats and rabbits have shown Boots IBS Relief hydrochloride not to be teratogenic, Boots IBS Relief is better avoided during pregnancy.
Boots IBS Relief precautions
Effects on the Ability to Drive or Operate Machinery: No studies on the effects on the ability to drive and use machines have been performed. The pharmacodynamic and pharmacokinetic profile as well as post-marketing experiences do not indicate any harmful effect of Boots IBS Relief on the ability to drive or to use machines.
Impairment of Fertility: There is no clinical data on male or female fertility; however, animal studies do not indicate harmful effects of Boots IBS Relief.
Use in pregnancy: There is no or limited amount of data from the use of Boots IBS Relief in pregnant women. Animal studies are insufficient with respect to reproductive toxicity. Boots IBS Relief is not recommended during pregnancy.
Use in lactation: It is unknown whether Boots IBS Relief or its metabolites are excreted in human milk. The excretion of Boots IBS Relief in milk has not been studied in animals. Boots IBS Relief should not be used while breastfeeding.
Use in children: Boots IBS Relief capsules are not recommended for use in children and adolescents <18 years, due to insufficient data on safety and efficacy.
- DrugBank. "Mebeverine". http://www.drugbank.ca/drugs/DB12554 (accessed September 17, 2018).
- MeSH. "Parasympatholytics". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology